The subject of the contract are Successive purchases and deliveries of medicines for the Wielkopolska Rheumatology Center SP SZOZ in Śrem. A detailed description of the subject of the contract is contained in Annexes 2.1-2.18 to the SWZ
The object of the order is pharmaceutical products - medicinesThe object of the order is pharmaceutical products - medicines
Detailed description of the item includes the assortment and price set out in Annex 2.1 to SWZ
The names of manufacturers and products used serve only to clarify the subject of the contract, and the order should be made of products indicated in the documentation or equivalent, indicating substitutes or biosimilars in the offer.
Successive Drug Purchases and Supplies to Drug Program — BARICYTINIB1. Successive purchases and deliveries of medicines to the drug program – BARICITINIB
2. A detailed description of the item is contained in the assortment and price annex constituting annex No. 2.10 to the SWZ
3. The names of manufacturers and products used serve only to clarify the subject of the contract, and the contract should be made of products indicated in the documentation or equivalent, indicating substitutes or biosimilars in the offer.
Successive purchases and delivery of medicines to the drug program — SEKUKINUMAB1. Successive purchases and deliveries of medicines for the drug program – SEKUKINUMAB
2. A detailed description of the item is included in the assortment and price annex constituting annex No. 2.11 to the SWZ
3. The names of manufacturers and products used serve only to clarify the subject of the contract, and the contract should be made of products indicated in the documentation or equivalent, indicating substitutes or biosimilars in the offer.
Successive Purchases and Delivery Immunoglobulin of Human Normal1. Successive purchases and deliveries of human normal immunoglobulin
2. A detailed description of the item is included in the assortment and price annex constituting annex No. 2.12 to the SWZ
3. The names of manufacturers and products used serve only to clarify the subject of the contract, and the contract should be made of products indicated in the documentation or equivalent, indicating substitutes or biosimilars in the offer.
Successive Drug Purchases and Supplies to Drug Program — UPADACITINIB1. Successive purchases and deliveries of medicines to the drug program – UPADACITINIB
2. A detailed description of the item is included in the assortment and price annex constituting Annex No. 2.13 to the SWZ
3. The names of manufacturers and products used serve only to clarify the subject of the contract, and the contract should be made of products indicated in the documentation or equivalent, indicating substitutes or biosimilars in the offer.
Successive Drug Purchases and Supplies to Drug Program — IKSEKIZUMAB1. Successive purchases and deliveries of medicines to the drug program – IKSEKIZUMAB
2. A detailed description of the item is contained in the assortment and price annex constituting Annex No. 2.14 to the SWZ
3. The names of manufacturers and products used serve only to clarify the subject of the contract, and the contract should be made of products indicated in the documentation or equivalent, indicating substitutes or biosimilars in the offer.
Successive purchases and deliveries of medicines to the drug program – UPADACITINIB in the period from 1.11.2022 to 31.12.20221. Successive purchases and deliveries of medicines to the drug program – UPADACITINIB in the period from 1.11.2022 to 31.12.2022
2. A detailed description of the item is included in the assortment and price annex constituting Annex No. 2.15 to the SWZ
3. The names of manufacturers and products used serve only to clarify the subject of the contract, and the contract should be made of products indicated in the documentation or equivalent, indicating substitutes or biosimilars in the offer.
Successive purchases and deliveries of medicines to the drug program – BARICITINIB in the period from 1.11.2022 to 31.12.20221. Successive purchases and deliveries of medicines to the drug program – BARICITINIB in the period from 1.11.2022 to 31.12.2022
2. A detailed description of the item is included in the assortment and price annex constituting Annex No. 2.16 to the SWZ
3. The names of manufacturers and products used serve only to clarify the subject of the contract, and the contract should be made of products indicated in the documentation or equivalent, indicating substitutes or biosimilars in the offer.
Successive purchases and deliveries of medicines to the drug program – TOCILIZUMAB in the period from 1.11.2022 to 31.12.20221. Successive purchases and deliveries of medicines to the drug program – TOCILIZUMAB in the period from 1.11.2022 to 31.12.2022
2. A detailed description of the item is included in the assortment and price annex constituting Annex No. 2.17 to the SWZ
3. The names of manufacturers and products used serve only to clarify the subject of the contract, and the contract should be made of products indicated in the documentation or equivalent, indicating substitutes or biosimilars in the offer.
Successive purchases and deliveries of medicines to the drug program – TOCILIZUMAB in the period from 1.11.2022 to 31.12.20221. Successive purchases and deliveries of medicines to the drug program – NINTEDANIB
2. A detailed description of the item is included in the assortment and price annex constituting Annex No. 2.18 to the SWZ
3. The names of manufacturers and products used serve only to clarify the subject of the contract, and the contract should be made of products indicated in the documentation or equivalent, indicating substitutes or biosimilars in the offer.
Successive purchases and deliveries of medicines for the drug program – TOCILIZUMAB1. Successive purchases and deliveries of medicines to the drug program – TOCILIZUMAB.
2. A detailed description of the item is included in the assortment and price annex constituting annex No. 2.2. to the SWZ
3. The names of manufacturers and products used serve only to clarify the subject of the contract, and the contract should be made of products indicated in the documentation or equivalent, indicating substitutes or biosimilars in the offer.
Successive Drug Purchases and Supplies to Drug Program — ETARNECEPT1. Successive purchases and deliveries of medicines to the drug program – ETARNECEPT.
2. A detailed description of the item is included in the assortment and price annex constituting Annex No. 2.3 to the SWZ
3. The names of manufacturers and products used serve only to clarify the subject of the contract, and the contract should be made of products indicated in the documentation or equivalent, indicating substitutes or biosimilars in the offer.
Successive purchases and deliveries of medicines for the drug program – CERTOLIZUMAB1. Successive purchases and deliveries of medicines to the drug program – CERTOLIZUMAB.
2. A detailed description of the item is included in the assortment and price annex constituting Annex No. 2.4 to the SWZ
3. The names of manufacturers and products used serve only to clarify the subject of the contract, and the contract should be made of products indicated in the documentation or equivalent, indicating substitutes or biosimilars in the offer.
Successive purchases and deliveries of medicines for the drug program – ADALIMUMAB1. Successive purchases and deliveries of medicines to the drug program – ADALIMUMAB
2. A detailed description of the item is included in the assortment and price annex constituting annex No. 2.5 to the SWZ
3. The names of manufacturers and products used serve only to clarify the subject of the contract, and the contract should be made of products indicated in the documentation or equivalent, indicating substitutes or biosimilars in the offer.
Successive Drug Purchases and Supplies to Drug Program — RITUXYMAB1. Successive purchases and deliveries of medicines for the drug program – RITUXIMAB
2. A detailed description of the item is contained in the assortment and price annex constituting Annex No. 2.6 to the SWZ
3. The names of manufacturers and products used serve only to clarify the subject of the contract, and the contract should be made of products indicated in the documentation or equivalent, indicating substitutes or biosimilars in the offer.
Successive Drug Purchases and Supplies to Drug Program — INFLIXIMAB1. Successive purchases and deliveries of medicines to the drug program – INFLIXIMAB
2. A detailed description of the item is included in the assortment and price annex constituting Annex No. 2.7 to the SWZ
3. The names of manufacturers and products used serve only to clarify the subject of the contract, and the contract should be made of products indicated in the documentation or equivalent, indicating substitutes or biosimilars in the offer.
Successive purchases and delivery of drugs to the drug program — GOLIMUMAB.1. Successive purchases and deliveries of medicines to the drug program – GOLIMUMAB.
2. A detailed description of the item is included in the assortment and price annex constituting Annex No. 2.8 to the SWZ
3. The names of manufacturers and products used serve only to clarify the subject of the contract, and the contract should be made of products indicated in the documentation or equivalent, indicating substitutes or biosimilars in the offer.
Successive Drug Purchases and Supplies to Drug Program — TOFACITINIB1. Successive purchases and deliveries of drugs to the drug program – TOFACITINIB
2. A detailed description of the item is included in the assortment and price annex constituting Annex No. 2.9 to the SWZ
3. The names of manufacturers and products used serve only to clarify the subject of the contract, and the contract should be made of products indicated in the documentation or equivalent, indicating substitutes or biosimilars in the offer.